Trials / Unknown
UnknownNCT05625568
Study of VYNT-0126 in the Treatment of Rett Syndrome in Adult Patients
Phase 2, Double-Blind, Randomized, Placebo-Controlled Clinical Study of VYNT-0126 in the Treatment of Rett Syndrome in Adult Female Patients
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Vyant Bio · Industry
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
This is an exploratory, Phase 2, multicenter, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, and efficacy of oral treatment with VYNT-0126 in female subjects 18-45 years of age with Rett syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VYNT-0126 | Liquid for oral administration once daily |
| DRUG | Placebo | Liquid for oral administration once daily |
Timeline
- Start date
- 2023-03-01
- Primary completion
- 2024-03-01
- Completion
- 2024-06-01
- First posted
- 2022-11-23
- Last updated
- 2022-11-23
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05625568. Inclusion in this directory is not an endorsement.